No Data
No Data
Is Heron Therapeutics (HRTX) a Good Investment Now?
Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported Earnings, And Analysts Cut Their Target Price
Heron Therapeutics Shares Are Trading Higher Following Better-than-expected Q4 Financial Results.
Northland Securities Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $9
Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (HRTX), Milestone Pharmaceuticals (MIST) and Personalis (PSNL)
Strong Week for Heron Therapeutics (NASDAQ:HRTX) Shareholders Doesn't Alleviate Pain of Five-year Loss